Skip to main content
SpringerLink
Log in

HPV-Impfung

  • Chapter
Die Gynäkologie

  • 15k Accesses

Zusammenfassung

Das Zervixkarzinom ist weltweit der zweithäufigste Krebs der Frau und zeigt Altersgipfel im 3. und 6. Lebensjahrzehnt (Parkin et al. 2005).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 199.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Ault KA (2007) Effect of prophylactic human papillomavirus L1 viruslike- particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369: 1861

    Article  PubMed  Google Scholar 

  • Baseman JG, Koutsky LA (2005) The epidemiology of human papillomavirus infections. J Clin Virol 32 Suppl 1: S16–24

    Article  PubMed  Google Scholar 

  • Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD et al. (2006) Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118: 2135–2145

    Article  PubMed  Google Scholar 

  • Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell- Lloyd S; New South Wales Health HPV Adverse Events Panel (2008) Anaphylaxis following quadrivalent human papillomavirus vaccination. Can Med Assoc J 179: 525–533

    Google Scholar 

  • Brown DR, Kjaer SK, Sigurdsson K et al. (2009) The Impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 viruslike particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16– 26 years. J Infect Dis 199: 926

    Article  PubMed  Google Scholar 

  • Castlellsagué X, de Sanjosé S, Aguado T, Louie KS, Bruni L, Muñoz J, Diaz M, Irwin K, Gacic M, Beauvais O, Albero G, Ferrer E, Byrne S, Bosch FX WHO (2007) HPV and cervical cancer in the world. 2007 Report. Vaccine 25, Suppl 3: C1–223 www.who.int/hpvcentre/publications/en

  • Centers for Disease Controll – CDC (2011) Reports of Health Concerns Following HPV Vaccination. [www.cdc.gov/vaccinesafety/Vaccines/HPV/gardasil.html]

  • Clifford GM, Gallus S, Herrero R et al. (2005) Worldwide distribution of huma papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366: 991

    Article  PubMed  CAS  Google Scholar 

  • Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F (2005) Carcinogenicity of human papillomaviruses. Lancet Oncol 6: 204

    Article  PubMed  Google Scholar 

  • De Vuyst H, Clifford G, Li N, Franceschi S (2009) HPV infection in Europe. Eur J Cancer 45 (15): 2632–2639 [Epub 2009 Aug 24]

    Google Scholar 

  • Doorbar J (2005) The papillomavirus life cycle. J Clin Virol 32 Suppl 1: S7–15

    Article  PubMed  CAS  Google Scholar 

  • Eddy DM (1990) Screening for cervical cancer. Ann Intern Med 113: 214–226

    PubMed  CAS  Google Scholar 

  • European Medicines Agency – EMA. Gardasil, European Public Assessment Report, EPARs for authorised medicinal products for human use 2006, Revision 4 [www.emea.europa.eu/humandocs/Humans/EPAR/gardasil/gardasil.htm]

  • European Medicines Agency – EMEA (2008) EMEA statement on the safety of Gardasil. [www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500015448.pdf ] Future II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356: 1915–1927

  • Future I/II Study Group; Dillner J, Kjaer SK, Wheeler CM et al. (2010) Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 341: c3493

    Google Scholar 

  • Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F et al. (2006) Enhanced humoral and memory B cellular immunity using HPV 16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24: 5937–49

    Article  PubMed  CAS  Google Scholar 

  • Gunther OP, Ogilvie G, Naus M et al. (2008) Protecting the next generation: What is the role of the duration of human papillomavirus vaccine-related immunity? J Infect Dis 197: 1653

    Article  PubMed  Google Scholar 

  • Harper DM (2008) Prophylactic human papillomavirus vaccines to prevent cervical cancer: review of the Phase II and III trials. Therapy 5: 313

    Article  CAS  Google Scholar 

  • Harper DM, Franco EL, Wheeler CM et al. (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367: 1247

    Article  PubMed  CAS  Google Scholar 

  • Haupt RM, Wheeler CM, Brown DR et al.; for the FUTURE I and II Investigators (2011) Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int J Cancer [Epub ahead of print]

    Google Scholar 

  • Hildesheim A, Herrero R, Wacholder S et al. (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine amongyoung women with preexisting infection: a randomized trial. JAMA 298: 743

    Article  PubMed  CAS  Google Scholar 

  • Hillemanns P, Petry KU, McAllister R, Büsch K, Largeron N. Vortrag »HPV (6, 11, 16 & 18)-Impfung als Primärprävention bei HPVbedingten Erkrankungen – eine Kosteneffektivitätsanalyse in Deutschland« (Informationsquelle: Sanofi MSD 2007)

    Google Scholar 

  • Ho GY, Studentsov YY, Bierman R, Burk RD (2004) Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 13: 110

    Article  PubMed  CAS  Google Scholar 

  • Insinga RP, Dasbach EJ, Elbasha EH (2009) Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis 9: 119

    Article  PubMed  Google Scholar 

  • Joura EA, Losch A, Haider-Angeler MG, Breitenecker G, Leodolter S (2000) Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J Reprod Med 45: 613–615

    PubMed  CAS  Google Scholar 

  • Joura EA, Leodolter S, Hernandez-Avila M et al. (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369: 1693

    Article  PubMed  CAS  Google Scholar 

  • Kirnbauer R, Booy F, Cheng N et al. (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89: 12180

    Article  PubMed  CAS  Google Scholar 

  • Klug SJ, Hukelmann M, Hollwitz B, Duzenli N, Schopp B, Petry KU et al. (2007) Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol 79: 616–625

    Article  PubMed  Google Scholar 

  • Koutsky LA., Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB et al. (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347: 1645–1651

    Article  PubMed  CAS  Google Scholar 

  • Lowy, DR, Schiller, JT (2006) Prophylactic human papillomavirus vaccines. J Clin Invest 116: 1167.

    Article  PubMed  CAS  Google Scholar 

  • Lu B, Kumar A, Castellsagué X, Giuliano AR (2011) Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infectious Diseases 11: 13

    Article  PubMed  Google Scholar 

  • Manhart LE, Holmes K K, Koutsky LA, Wood TR, Kenney DL, Feng Q et al. (2006) Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sexually Transm Dis 33: 502–508

    Article  Google Scholar 

  • Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ et al. (2006) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107: 18–27

    Article  PubMed  Google Scholar 

  • Markowitz LE (2007) HPV vaccines prophylactic, not therapeutic. JAMA 298: 805

    Article  PubMed  CAS  Google Scholar 

  • Markowitz LE, Dunne EF, Saraiya M et al. (2007) Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56: 1

    PubMed  Google Scholar 

  • Munger K, Howley PM (2002) Human papillomavirus immortalization and transformation functions. Virus Res 89: 213–228

    Article  PubMed  CAS  Google Scholar 

  • Munoz N, Mendez F, Posso H et al. (2004) Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 190: 2077

    Article  PubMed  Google Scholar 

  • Munoz N, Manalastas R Jr, Pitisuttithum P et al. (2009) Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet 373: 1949

    Article  PubMed  CAS  Google Scholar 

  • Paavonen J, Jenkins D, Bosch FX et al. (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369: 2161

    Article  PubMed  CAS  Google Scholar 

  • Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group, Greenacre M (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374: 301–14 [Epub 2009]

    Google Scholar 

  • Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74

    Article  PubMed  Google Scholar 

  • Partridge JM, Koutsky LA (2006) Genital human papillomavirus infection in men. Lancet Infect Dis 6: 21–31

    Article  PubMed  Google Scholar 

  • Pathirana D, Hillemanns P, Petry KU et al. (2008) Impfprävention HPVassoziierter Neoplasien. S3-Leitlinie der Arbeitsgruppe HPV-Management- Forum der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. Chemother J 17:120–71 [www.chemotherapiejournal.de/archiv/artikel/2008/04/216.html]

  • Paul-Ehrlich-Institut (2008) Gardasil: Stellungnahme zum unklaren Todesfall aus Deutschland in zeitlichem Zusammenhang zu einer Gardasil-Impfung. [www.pei.de/DE/infos/fachkreise/am-infos-ablage/sik/2008-01-18-gardasil.html]

  • Paul-Ehrlich-Institut (2008) Informationen zu den Untersuchungsergebnissen der beiden Todesfälle aus Deutschland und Österreich. [www.pei.de/cln_092/nn_158154/DE/infos/fachkreise/impfungen-impfstoffe/hpv/obduktion.html]

  • Robert Koch-Institut – RKI (2007) Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren – Empfehlung und Begründung. Epidemiol Bull 12/2007

    Google Scholar 

  • Sanders GD, Taira AV (2003) Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9: 37

    Article  PubMed  Google Scholar 

  • Schwarz T, Wurzburg J (2006) An ASO4-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15 to 55 years old. Presented at the 42nd annual meeting of the American Society of Cancer Oncology, June 2–6, 2006, Atlanta, GA [Abstract #1008]

    Google Scholar 

  • Sigurdsson K (1999) The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995. Acta Obstet Gynecol Scand 78: 478–485

    Article  PubMed  CAS  Google Scholar 

  • Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun M, Markowitz LE, Iskander J (2009) Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 302: 750–757

    Article  PubMed  CAS  Google Scholar 

  • Smith JS, Backes DM, Hoots BE, Kurman RJ, Pimenta JM (2009) Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol 113: 917–924

    PubMed  Google Scholar 

  • Smith JS, Gilbert PA, Melendy A, Rana RK, Pimenta JM (2011) Age-specific prevalence of human papillomavirus infection in males: a global review. J Adolesc Health 48: 540–552

    Article  PubMed  Google Scholar 

  • Stanley M (2006) Immune responses to human papillomavirus. Vaccine; 24 Suppl 1: S16

    Article  PubMed  Google Scholar 

  • Trottier H., Franco EL 2006) The epidemiology of genital human papillomavirus infection. Vaccine 24 Suppl 1: S1–15

    PubMed  Google Scholar 

  • Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR et al. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebocontrolled multicentre phase II efficacy trial. Lancet Oncol 6: 271–278

    Article  PubMed  Google Scholar 

  • Villa LL, Ault KA, Giuliano AR et al. (2006a) Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 24: 5571

    Article  CAS  Google Scholar 

  • Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE et al. (2006b) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95: 1459–1466

    Article  CAS  Google Scholar 

  • Vilos GA (1998) The history of the Papanicolaou smear and the odyssey of George and Andomache Papanicolaou. Obstet Gynecol 91: 479–483

    Article  PubMed  CAS  Google Scholar 

  • Viscidi RP, Schiffman M, Hildesheim A et al. (2004) Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 13: 324

    Article  PubMed  Google Scholar 

  • Wheeler CM, Kjaer SK, Sigurdsson K et al. (2009) The Impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16– 26 years. J Infect Dis 199: 936

    Article  PubMed  Google Scholar 

  • zur Hausen H (2009) Papillomaviruses in the causation of human cancers – a brief historical account. Virology 384: 260–265

    Article  PubMed  Google Scholar 

Internetadressen

Download references

Author information

Authors and Affiliations

  1. Klinikum St. Marien, Lehrkrankenhaus der Universität Regensburg und der Friedrich-Alexander-Universität Erlangen-Nürnberg, Frauenklinik, Mariahilfbergweg 5–7, 92224, Amberg

    Prof. Dr. med. A. Scharl

  2. Johanniter-Krankenhaus Gynäkologisch-geburtshilfliche Abteilung, Evangelisches Klinikum Bonn gGmbH, Johanniterstraße 3–5, 53113, Bonn

    Prof. Dr. med. U.-J. Göhring

Authors
  1. Prof. Dr. med. A. Scharl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. U.-J. Göhring
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Johann-Wolfgang-Goethe-Universität Frankfurt, Universitätsfrauenklinik, Frankfurt

    Manfred Kaufmann

  2. Otto-von-Guericke-Universität Magdeburg, Universitätsfrauenklinik, Magdeburg

    Serban D. Costa

  3. Friedrich-Alexander-Universität Erlangen-Nürnberg, Klinikum St. Marien, Lehrkrankenhaus der Universität Regensburg, Erlangen-Nürnberg

    Anton Scharl

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Scharl, A., Göhring, UJ. (2013). HPV-Impfung. In: Kaufmann, M., Costa, S.D., Scharl, A. (eds) Die Gynäkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-20923-9_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-20923-9_22

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-20922-2

  • Online ISBN: 978-3-642-20923-9

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation